tailieunhanh - Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (VEGFR2 and c-MET inhibitor), was shown to have efficacy on bone lesions in patients. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN